QTEX at a glance
The past year
Chart+14.3% $1.12, close Nov 19
- From the highest close
- −63.6%
- Vs the 200-day average
- +13.0%
Short interest
History3.6M shares
- Since the last report
- −16.9%
- Days to cover
- 1.0 day
- Settled
- Oct 30, 2026
Insider buying, 7 days
FilingsNone filed this week
- Form 4s filed
- Nov 14 – Nov 20
Understand the Business
Why the Stock Moved
Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.
QTEX price history
Loading recent earnings…
Investment thesis
What must happen next
QTEX’s core product must move from initial or pilot demand into repeatable medical-instrument adoption by hospitals, distributors, or strategic partners.HoldingMateriality: High
GAAP annual revenue was $289,000 in FY2025 after $0 in FY2024 and $0 in FY2023, indicating the first observable commercial or customer activity. If adoption becomes repeatable, the company can start building an operating business; if it remains pilot-like, the equity is mainly funding R&D with little proof of market pull.
Watch: Hospitals or distributors treat the product as experimental and do not move beyond small pilots or evaluations.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP annual revenue was $289,000 in FY2025 after $0 in FY2024 and $0 in FY2023, indicating the first observable commercial.
Open source ↗QTEX must prove that its medical-instrument sales carry product value and manufacturing leverage, not merely low-margin prototype or pilot revenue.WeakeningMateriality: High
GAAP annual gross profit turned positive in FY2025 but was only $2,000 on $289,000 of revenue. Revenue without gross margin will not fund R&D, sales support, regulatory work, or shareholder value creation.
Watch: Contract manufacturing, installation, service, or warranty costs absorb most of the selling price as volume rises.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP annual gross profit turned positive in FY2025 but was only $2,000 on $289,000 of revenue.
Open source ↗QTEX must secure enough capital, partnerships, or non-dilutive funding to bridge the commercialization period without transferring most future upside away from existing shareholders.WeakeningMateriality: Medium
Cash was $3.159 million at FY2025 year-end, down from $5.111 million at FY2024 year-end. Even if the product eventually works, shareholders can still lose if the company must finance years of burn on punitive terms.
Watch: Public-equity market access closes or Nasdaq liquidity weakens before commercial proof improves.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Cash was $3.159 million at FY2025 year-end, down from $5.111 million at FY2024 year-end.
Open source ↗Management must convert a persistent development and overhead cost base into commercial proof rather than simply extending operating losses.WeakeningMateriality: Medium
GAAP annual operating income was negative $13.623 million in FY2025, negative $11.267 million in FY2024, and negative $12.133 million in FY2023. A stable burn rate can be rational during product development, but it becomes value-destructive if it does not produce adoption, margin, or strategic validation.
Watch: R&D, regulatory, and G&A spending rises to support a broader product roadmap before the first product proves market fit.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP annual operating income was negative $13.623 million in FY2025, negative $11.267 million in FY2024, and negative $12.133 million in.
Open source ↗
Full investment case & evidence
Loading the original research archive…
Original research
QTEX’s core product must move from initial or pilot demand into repeatable medical-instrument adoption by hospitals, distributors, or strategic partners. If adoption becomes repeatable, the company can start building an operating business; if it remains pilot-like, the equity is mainly funding R&D with little proof of market pull.
QTEX must prove that its medical-instrument sales carry product value and manufacturing leverage, not merely low-margin prototype or pilot revenue. Revenue without gross margin will not fund R&D, sales support, regulatory work, or shareholder value creation.
QTEX must secure enough capital, partnerships, or non-dilutive funding to bridge the commercialization period without transferring most future upside away from existing shareholders. Even if the product eventually works, shareholders can still lose if the company must finance years of burn on punitive terms.
Management must convert a persistent development and overhead cost base into commercial proof rather than simply extending operating losses. A stable burn rate can be rational during product development, but it becomes value-destructive if it does not produce adoption, margin, or strategic validation.
All standing thesis claims
Original report summary
early revenue turns into repeatable, higher-margin adoption before cash needs force punitive dilution.
Bull case and bear case
Bull case and bear case for QTREX Quantum
Where the evidence on QTREX Quantum disagrees: Mixed on the latest evidence (Oct 15, 2026). Of its 4 thesis points, 1 holding and 3 weakening.
Bull case: what the evidence supports
QTEX’s core product must move from initial or pilot demand into repeatable medical-instrument adoption by hospitals, distributors, or strategic partners.
Bear case: what the evidence questions
QTEX must prove that its medical-instrument sales carry product value and manufacturing leverage, not merely low-margin prototype or pilot revenue.
QTEX must secure enough capital, partnerships, or non-dilutive funding to bridge the commercialization period without transferring most future upside away from existing shareholders.
Management must convert a persistent development and overhead cost base into commercial proof rather than simply extending operating losses.
Thesis-Break Engine
Thesis-break watch · QTREX Quantum
OptimistFi is watching QTREX Quantum. No break-condition checks are on record yet — they accumulate as new filings are checked.
MARKET + FINANCIAL SNAPSHOT
The numbers behind the thesis
What Changed
- MixedForeign issuer material report (6-K).
QTREX Quantum filed an SEC report on 2026-10-09: Foreign issuer material report (6-K). It is a dated development that tests the current thesis.
- MixedForeign issuer material report (6-K).
QTREX Quantum filed an SEC report on 2026-10-01: Foreign issuer material report (6-K). It is a dated development that tests the current thesis.
- MixedForeign issuer material report (6-K).
QTREX Quantum filed an SEC report on 2026-09-24: Foreign issuer material report (6-K). It is a dated development that tests the current thesis.
Risks / falsifiers
What could break the thesis
- Hospitals or distributors treat the product as experimental and do not move beyond small pilots or evaluations.
- Contract manufacturing, installation, service, or warranty costs absorb most of the selling price as volume rises.
- Public-equity market access closes or Nasdaq liquidity weakens before commercial proof improves.
- R&D, regulatory, and G&A spending rises to support a broader product roadmap before the first product proves market fit.
QTEX news
Loading headlines…
Financial statements
QTEX income statement
Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.
QTEX: quick answers
- What is QTEX's short interest?
- As of October 30, 2026, 3.6M QTEX shares were sold short, down 16.9% from the count before. At the stock's average daily volume that is 1.0 day to cover. FINRA publishes the count twice a month. QTEX short interest history

